SCHEMBL8745767

SCHEMBL8745767

Cc1ccc2nc(C(=O)C(C)C)ccc2c1Br

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 3/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
DHODH Q02127 3/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33
KMT2A Q03164 3/20 0.33
RXFP1 Q9HBX9 3/20 0.32
MEN1 O00255 2/20 0.32
NPC1 O15118 2/20 0.32
HTT P42858 1/20 0.32
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32
PRNP P04156 1/20 0.31
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8778506 0.78 PLA2G2D (0.32) ALDH1A1SMN1; SMN2DHODHHTT
SCHEMBL14747554 0.78 PPARA (0.33) ALDH1A1SMN1; SMN2KDM4ERAB9AKMT2A
SCHEMBL14747560 0.74 PTPN1 (0.36) ALDH1A1KDM4EMAPT
SCHEMBL8745762 0.73 KDM4E (0.39) ALDH1A1SMN1; SMN2KDM4EMAPTRAB9A
SCHEMBL25735716 0.73 NOS3 (0.39) KDM4EMAPTRAB9ATDP1GAA
SCHEMBL2723291 0.72 BACE1 (0.46) ALDH1A1SMN1; SMN2RAB9ADHODHKMT2A
SCHEMBL14573271 0.72 KDM4E (0.42) ALDH1A1KDM4EMAPTRAB9AKMT2A
SCHEMBL14573267 0.71 ALDH1A1 (0.51) ALDH1A1KDM4ERAB9AKMT2AESR1
SCHEMBL15294421 0.70 HSD17B14 (0.51) ALDH1A1SMN1; SMN2MAPTRAB9AKMT2A
SCHEMBL8745732 0.69 NOTUM (0.36) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2018-08-09 US disclosed
US-20170143694-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2017-05-25 US disclosed
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-05-01 US disclosed
US-8623892-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-01-07 US disclosed
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2013-07-18 US disclosed
US-8389543-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2013-03-05 US disclosed
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ALDH1A1 289/4885SMN1; SMN2 1142/4885KDM4E 3322/4885
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ALDH1A1 289/4885SMN1; SMN2 1142/4885KDM4E 3322/4885
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ALDH1A1 289/4885SMN1; SMN2 1142/4885KDM4E 3322/4885
US-20170143694-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ALDH1A1 289/4885SMN1; SMN2 1142/4885KDM4E 3322/4885
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ALDH1A1 289/4885SMN1; SMN2 1142/4885KDM4E 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.